Optimizing tacrolimus dosage in post-renal transplantation using DoseOptimal framework: profiling CYP3A5 genetic variants for interpretability
- 21 March 2025
- journal article
- research article
- Published by Springer Nature in International Journal of Clinical Pharmacy
- Vol. 47 (4) , 1042-1052
Abstract
Background Achieving optimal tacrolimus dosing is vital for effectively balancing therapeutic efficacy and safety, as CYP3A5 genetic variants and inter-patient variability emphasize the need for precision strategies. Aim This study aimed to optimize tacrolimus dosage prediction for renal transplant recipients by incorporating genetic polymorphisms, specifically profiling CYP3A5 genetic variants, within the DoseOptimal framework to enhance interpretability and accuracy of dosing decisions. Method The dataset comprised clinical, demographic, and CYP3A5 genetic variants information from 1045 stable tacrolimus-treated patients. The DoseOptimal framework was developed by integrating the strengths of the most effective algorithms from fifteen machine learning models. SHapley Additive exPlanations (SHAP) and decision tree insights were incorporated to enhance the framework’s interpretability. The framework’s performance was assessed using mean absolute error (MAE) and the coefficient of determination (R2 score). The F-statistic and p value were calculated to validate the framework’s statistical significance. Results The DoseOptimal framework demonstrated robust performance with an R2 score of 0.884 in the training set and 0.830 in the testing set. The MAE was 0.40 mg/day (95% CI 0.38–0.43) in the training set and 0.41 mg/day (95% CI 0.38–0.45) in the testing set. The framework predicted the ideal tacrolimus dosage in 87.6% (n = 275) of the test cohort, with 3.2% (n = 10) underestimation and 9.2% (n = 29) overestimation. The framework’s statistical significance was confirmed with an F-statistic of 266.095 and a p value < 0.001. Conclusion The framework provides precision medicine-based dosing solutions tailored to individual genetic profiles, minimizing dosing errors and enhancing patient outcomes.Keywords
This publication has 54 references indexed in Scilit:
- Tacrolimus Exposure Prediction Using Machine LearningClinical Pharmacology & Therapeutics, 2020
- A Machine Learning-Based Identification of Genes Affecting the Pharmacokinetics of Tacrolimus Using the DMETTM Plus PlatformInternational Journal of Molecular Sciences, 2020
- Long-Term Kidney Transplant Outcomes: Role of Prolonged-Release TacrolimusTransplantation Proceedings, 2020
- Increasing Time in Therapeutic Range of Tacrolimus in the First Year Predicts Better Outcomes in Living-Donor Kidney TransplantationFrontiers in Immunology, 2019
- Early Tacrolimus Concentrations After Lung Transplant Are Predicted by Combined Clinical and Genetic Factors and Associated With Acute Kidney InjuryClinical Pharmacology & Therapeutics, 2019
- Interpretation of Compound Activity Predictions from Complex Machine Learning Models Using Local Approximations and Shapley ValuesJournal of Medicinal Chemistry, 2019
- CYP3A5*3andABCB161A>G Significantly Influence Dose‐adjusted Trough Blood Tacrolimus Concentrations in the First Three Months Post‐Kidney TransplantationBasic & Clinical Pharmacology & Toxicology, 2018
- Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus DosingClinical Pharmacology & Therapeutics, 2015
- Predicting warfarin dosage from clinical data: A supervised learning approachArtificial Intelligence in Medicine, 2012
- Association of ABCB1, CYP3A4*18B and CYP3A5*3 genotypes with the pharmacokinetics of tacrolimus in healthy Chinese subjects: a population pharmacokinetic analysisJournal of Clinical Pharmacy and Therapeutics, 2010